30 closest matches · ranked by relevance
Breast Cancer
Primary: Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. — 14.3 months
Breast Cancer
Primary: Overall Response Rate (ORR) — 35.6; 13.2 percentage of participants — p=0.42
Breast Cancer
Primary: Number of Participants With Tumor Response (Stable Disease) — 5 participants
Breast Cancer
Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010
Advanced Breast Cancer · HER2-positive Breast Cancer · Brain Metastases
Primary: 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) — 1; 7 Participants
Breast Cancer Metastatic
Primary: Clinical Benefit Rate at 24 Weeks — 3; 18; 9 Participants
Breast Cancer
Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants
HER2+ Metastatic Breast Cancer (MBC)
Primary: Centrally Assessed Progression Free Survival — 8.8; 6.6 months — p=0.0059
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.8; 31.0; 55.6 percentage of participants
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study) — 3; 13; 10; 11 Participants
Metastatic Breast Cancer
Primary: Objective Response Assessed by the Independent Review Facility Using Response Evaluation Criteria in Solid Tumors (RECIST) — 25.7; 26.9 Percentage of patients
Neoplasms, Breast
Primary: Progression Free Survival (PFS) Events in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI) — 62; 75; 7; 3 Participants…
Breast Neoplasms
Primary: Objective Response (OR) — 4 Participants
Disseminated HER2+ Breast Cancer
Primary: The Patient Clinical Profile (General Clinical Data and Breast Cancer Characteristics) — 63.5; 48.8; 84.1; 41.1 percentage of participants
Metastatic Breast Cancer
Primary: Percentage of Participants With an Objective Response as Assessed Through Independent Radiologic Review — 32.7; 32.7 percentage of participants
HER2-positive Breast Cancer · Breast Cancer · Breast Cancer Stage
Primary: Estimate Progression-free Survival — 16.9; 8.3 Months
Breast Cancer
Primary: Hematological - Dose Limiting Toxicities — 1; 3; 7; 1 participants
Breast Cancer
Primary: Overall Response Rate (ORR) — 30 percentage of participants
Metastatic Breast Cancer
Primary: Percentage of Participants With Adverse Events (AE), Serious Adverse Events (SAE), AEs With Grade >=3, and AEs Related To Treatment — 100; 100; 100; 100 percentage of…
Breast Cancer
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0…
Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Grades of Cardiotoxicity Events in the Subset of Patients Reporting a Cardiotoxicity Event — 2; 12; 4; 8 participants
Metastatic Breast Cancer
Primary: Overall Survival (PP Population) — 30.2; 26.1 months — p=0.1983
HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Primary: Severity of Adverse Events — 53; 40; 18; 2 Participants
Breast Cancer
Primary: Primary Endpoint : Compare Best Overall Response Rate (ORR) (According to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 Criteria) at Week 24 of MYL-1401O Plus…
Breast Cancer
Primary: Part I: Progression Free Survival (PFS) by Biomarker — NA; NA; 13.963; 1.216 months
Metastatic Breast Cancer
Primary: Dose-Limiting Toxicity (DLT) of MK-3475 in Combination With Trastuzumab — 0; 0 Participants
Breast Cancer Metastases · HER2 Positive Breast
Primary: Percentage of Patients With HER2- Primary Breast Cancer Who Develop Imagable HER2+ Metastases — 13 % of participants
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
HER2-positive Breast Cancer · Recurrent Breast Cancer · Stage IIIA Breast Cancer
Primary: Dose Limiting Toxicity (DLT) of Dose-escalating BYL719 in Combination With T-DM1 — 0; 1; 0; 2 Participants
Breast Cancer
Primary: Percentage of Participants With Adverse Events of Primary Interest (AEPIs) — 23.1; 51.4 Percentage of Participants